Financial Feasibility of BPaL(M) Under Pretomanid Price Scenarios - China, 2023-2024.

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: The BPaL(M) regimen is a World Health Organization (WHO)-endorsed, all-oral, shorter treatment for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) recently approved in China; however, its large-scale implementation depends on affordability and sustainability within the national health insurance system.

WHAT IS ADDED BY THIS REPORT?: This study identifies 26,000 Chinese Yuan (CNY) per course as an approximate break-even pretomanid price for health insurance reimbursement in China. Lower prices can generate savings for both insurers and patients.

WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: Pretomanid price negotiations should be combined with reimbursement and financial protection policies to support equitable scale-up of BPaL(M).